| Genetronics Biomedical Corporation is the world leader in electroporation therapy with 216 patents issued, allowed, or pending. The Company utilizes its proprietary electroporation technology for the targeted intracellular delivery of therapeutic materials, concentrating on drugs, vaccines, and gene therapy. In oncology, Genetronics has initiated Phase III clinical trials for the treatment of recurrent head & neck cancer. In gene therapy, Genetronics has several collaborations with major biotechnology and pharmaceutical companies for the delivery of therapeutic genes or vaccines using electroporation. Genetronics' BTX® Division, a leader in molecular delivery, features electroporation and electro fusion technology for research laboratory markets worldwide. |
